FDA reviews Eli Lilly's lung cancer drug necitumumab; Catabasis gets fast track for DMD drug;

@FierceBiotech: Who should make this year's Fierce 15? Nominate the most promising private biotechs. Nomination form | Follow @FierceBiotech

@JohnCFierce: Aimmune joins the biotech IPO scrum in search of $115M--plus a roundup of biotech IPO news. More | Follow @JohnCFierce

@DamianFierce: $AGN is paying $MRK $250M to become the roughly 127th company developing CGRP blockers for migraine. Release | Follow @DamianFierce

> The FDA issued its internal review of Eli Lilly's cancer drug necitumumab today, noting some serious safety issues and a marginal gain in survival rates. The review includes a review of two studies for the drug, one of which was stopped due to safety factors. Eli Lilly ($LLY) has submitted data from a separate study that concludes patients taking the drug along with a chemo combo gained a 1.6-month advantage in terms of overall survival rates. External FDA experts will vote on the drug--designed for non-small cell lung cancer--following a panel discussion on Thursday. Reuters reports that  analysts expect the drug can deliver $582 million in annual sales by 2020, if it's approved. Story

> Cambridge, MA-based Catabasis says that CAT-1004 has received Fast Track designation from the FDA for the treatment of Duchenne muscular dystrophy. Release

Medical Device News

@FierceMedDev: Natera bags $180M in IPO to ramp up R&D. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: ICYMI last week: FDA warns that Maquet's anesthesia system could lead to a fatal stop in ventilation. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI from FierceDiagnostics: BG Medicine gets FDA blessing for automated chronic heart failure test. Article | Follow @EmilyWFierce

> DEKA gets $7M from DARPA to develop prosthetic arm with a sense of touch. News

> Report: Repeal of medical device tax gaining traction in Congress. More

Pharma News

@FiercePharma: Horizon targets Depomed's pain portfolio with $3B hostile bid. News | Follow @FiercePharma

@EricPFierce: Don't miss our July 8 Twitter chat on sustained release with BASF expert Thorsten Cech. Details are here | Follow @EricPFierce

@CarlyHFierce: ICYMI from FiercePharmaMarketing: Expecting payer pushback, Vertex to field new CF med Orkambi at $259K. Report | Follow @CarlyHFierce

> AstraZeneca and Cephalon pony up $50M+ to settle Medicaid pricing claims. News

> Doctor faces sentencing for 'over the top' cancer drug dosing. Item

> Mylan didn't disclose director's ties to HQ land deal: WSJ. Report

Drug Delivery News

> Natural bioluminescence provides inside look at drug-cell interactions. Story

> FDA to review modified-release version of Pfizer's Xeljanz for rheumatoid arthritis. More

> Novo ends microneedle patch diabetes partnership with Zosano. Article

> UCSB team tackles aggressive kidney disease by hitching a ride into cysts. Story

> China's Wuzhou says it will take 10% stake in oral insulin specialist Oramed for $52M. Report

Pharma Manufacturing News

> India's Lupin gets Russian production site in deal for Biocom. More

> Boehringer Ingelheim unloads vet plant in Iowa to contract manufacturer. Story

> FDA warns consumers to check any generic Valium bought online; it may be dangerous. Article

> Actavis yanks more than half a million boxes of birth control pills for packaging faux pas. News

> Europe says Israel and Brazil can ship APIs without having to certify them. Item

Pharma Asia News

> China's Guangxi Wuzhou builds stake in Israel's Oramed with diabetes in focus. More

> Shanghai, Shenzhen IPO halts won't spoil the China healthcare party. Story

> More trouble for India's CROs as Quest Life Sciences hauled up by WHO in HIV trial. Report

> Indian court upholds BMS Sprycel patent, but list of challengers grows. News

> Alibaba Health plans wider online sales push in China as competition heats up. Article